UK Life Sciences and Healthcare Newsletter: Life Sciences: What's new in France? Avastin/Lucentis case: French Competition Authority imposes record fine of 444 million euros on Novartis and Roche for alleged abuse of collective dominant position

Published date28 January 2021
Subject MatterCompetition,Life Sciences,Infringement,Off-Label Use,Biotechnology,Enforcement Actions,Novartis,Genentech,France,Pharmaceutical Industry,French Competition Authority
AuthorMélanie Thill-Tayara,Marion Provost
Law FirmDechert LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT